Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546955 | 1.00 | CYP11B2 (0.56) | CYP11B2MEN1KMT2AHSD11B1MAPT | |
| SCHEMBL18790962 | 0.71 | CYP11B2 (0.45) | CYP11B2GRIN2BDEGS1 | |
| SCHEMBL18790706 | 0.69 | CYP11B2 (0.72) | CYP11B2GRIN1GRIN2B | |
| SCHEMBL18790963 | 0.66 | DRD4 (0.57) | CYP11B2DEGS1 | |
| SCHEMBL18790986 | 0.65 | CYP11B2 (0.65) | CYP11B2GRIN2BL3MBTL1DYRK1A | |
| SCHEMBL18791082 | 0.64 | CYP11B2 (0.68) | CYP11B2MAPTL3MBTL1DYRK1A | |
| SCHEMBL18790961 | 0.64 | DRD4 (0.51) | CYP11B2MAPTTSHR | |
| SCHEMBL22236832 | 0.63 | CHRNB2 (0.67) | — | |
| SCHEMBL18791006 | 0.63 | CYP11B2 (0.42) | CYP11B2MEN1KMT2AMAPTDYRK1A | |
| SCHEMBL18566616 | 0.62 | CYP11B2 (0.79) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381904-B1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-07-28 | — | — | EP | claimed |
| EP-3381904-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-10-03 | — | — | EP | claimed |
| EP-3381904-B1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | REN, NR3C2, NR5A1 | CYP11B2 8/4885MEN1 734/4885KMT2A 3211/4885 |
| US-20180312503-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | REN, NR3C2, NR5A1 | CYP11B2 8/4885MEN1 1013/4885KMT2A 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.